投资风险 - 投资股票并不是每一项投资都会成功，长期投资者只需有几个大赢家来平衡其他投资的损失[1] - CVS Health Corporation (NYSE:CVS)的股价表现落后于标普500指数，投资个股的最低要求是要超过指数[2] 财务表现 - CVS在2023财年报告了稳健的营收增长，但在2022年受到阿片类诉讼费用和资产减值的影响[4] - CVS的三个业务部门中，只有Health Services部门在财年2023实现了营收和调整后的营业收入的增长[7] - CVS在2024财年的指导预期被调低，尤其是调低了长期财务指导[8] 未来展望 - CVS预计未来几年每年调整后每股收益将增长约6%，其中约3%至4%来自营业收入增长，约2%来自股票回购[11] - CVS被认为是被低估的，目前的估值倍数低于10年平均值，估值倍数约为10意味着企业无法再增长[14] - 尽管认为CVS未来增长可能会受到限制，但由于低估值仍被认为是值得持有的股票，预计未来几年会表现出色[21] 零售业务挑战 - CVS在零售业务中面临竞争问题，管理层对未来持悲观态度，预计Pharmacy & Consumer Wellness部门将对调整后每股收益产生负面影响[19] - CVS在零售业务中缺乏定价权，这对公司不利，该部门在2023财年贡献了近33%的总收入和34%的总营业收入[20]

JHVEPhoto CVS Health (NYSE:CVS), along with the rest of the healthcare services sector, is having a tough start to 2024. Cyberattacks, regulatory scrutiny, declining COVID-related sales, elections, and lower CMS rates, are colliding with the company's higher medical care costs, implementation struggles, and leadership changes. With so many headwinds, it's natural to expect better times ahead, but is it the right expectation? Let's dive in. Introduction I've been covering CVS on Seeking Alpha since March of ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about CVS Health (CVS) .CVS Health currently has an average brokerage r ...

Becoming richer by investing in stocks usually doesn't happen overnight. It takes years -- sometimes decades -- of patience and holding on to shares of companies that aren't always performing as well as you'd like. That's an important part of the process. Investors shouldn't give up on stocks that aren't keeping pace with the market for a year or two, provided these stocks have solid prospects.Let's consider two companies that have lagged the market over the trailing 12 months but are still worth buying: CV ...

CVS Health (CVS) closed at $74.30 in the latest trading session, marking a -0.05% move from the prior day. This change lagged the S&P 500's 1.03% gain on the day. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated Nasdaq saw an increase of 1.51%.Coming into today, shares of the drugstore chain and pharmacy benefits manager had lost 2.25% in the past month. In that same time, the Retail-Wholesale sector gained 3.93%, while the S&P 500 gained 3.21%.Investors will be eagerly watching ...

CVS Health Corporation (NYSE:CVS) 45th Annual Raymond James Institutional Investors Conference Transcript March 5, 2024 9:50 AM ET Executives Tom Cowhey - Executive Vice President and CFO Analysts Unidentified Analyst So I’ve been doing these 25 years and they have to tell me where the on button is for the mic, so equity professional. So, good morning, everybody. We’re very happy to have CVS back after a lengthy absence. I don’t think Larry Merlo felt the greatness last time he was here, so they boycotted u ...

业绩总结 - CVS在2024年的业务表现符合预期，特别是在Medicare方面[4] - 公司在Obamacare交易所业务中取得了显著增长，通过合作产品推动了药店和诊所的利用率[7] - Oak Street在2023年表现出色，公司计划加速开设诊所以应对V28的挑战[7] 用户数据 - CVS计划通过多项措施来恢复Medicare业务的利润率[2] - 公司通过收购获得了先进的初级护理、医生增强和家庭服务能力[6] 未来展望 - 2025年CVS计划通过多项措施来恢复Medicare业务的利润率[2] - 公司认为自身在PBM领域的地位具有较强的可持续性和盈利性，尽管面临一些挑战[8] 新产品和新技术研发 - CVS计划通过CostVantage项目来改变药品定价结构[4] - 公司通过整合Aetna Caremark产品，公司看到了低医院入院率和更好的药物依从性等好处[7] 市场扩张和并购 - 公司通过收购获得了先进的初级护理、医生增强和家庭服务能力[6] - 公司在Obamacare交易所业务中取得了显著增长，通过合作产品推动了药店和诊所的利用率[7] 负面信息 - Change Healthcare的问题对CVS的影响主要体现在Medicaid业务上[1] - CMS对Medicare Advantage的定价方式可能会对CVS的业务产生影响[3]

新心律失常测试推出 - CVS Health旗下的Signify Health最近推出了一项新的心律失常测试[1] - 该测试的推出扩展了公司的诊断和预防服务[1] - Signify Health的新测试可以识别患有心律失常风险的成员，并进行心脏活动的持续监测[4] 心律失常的重要性 - 早期在家检测房颤可以帮助减轻症状和更严重的并发症[2] - 未被诊断的心律失常患者可能出现胸痛、心跳急促和不规则、呼吸急促等症状，以及中风和糖尿病等高风险疾病[3] - 早期识别心律失常对于减少心力衰竭或中风等并发症的风险至关重要[6] 市场趋势和公司发展 - 使用连续ECG贴片筛查心律失常可以提升会员体验和促进更好的结果[5] - 全球心律失常市场预计将在2030年以6.8%的复合年增长率增长，受到吸烟、过度饮酒和肥胖等生活方式选择增加的影响[8] - Signify Health继续展示其在家康复能力的价值，为所有多付款人医疗保险合作伙伴提供服务[9] - CVS Health通过利用Signify在其他产品中的强大能力，包括个人交换和医疗补助，扩大了其可寻址市场[10] - 公司正在消除数字采用的障碍，使客户更容易访问他们寻求的服务，如在线药房补充和预约接种[11] 股价表现和评级 - CVS在过去六个月中的股价上涨了14.8%，超过了行业的上涨幅度[12] - CVS Health目前持有Zacks Rank 3（持有）[13]

ToplineCVS and Walgreens will begin selling the abortion pill mifepristone at pharmacies across select states in the coming weeks, as the Supreme Court gears up to hear oral arguments about the drug at the end of the month.The chains will sell the drug at pharmacies across several states. Corbis via Getty Images Key FactsThe pharmacy chains received certification from the Food and Drug Administration to dispense the pill, according to the New York Times, which originally reported the news. CVS said it is w ...

药店提供堕胎药米非司酮 - CVS和Walgreens将在一些州的药店开始提供堕胎药米非司酮[1] - 两家最大的药店连锁店表示他们已经获得了FDA去年发布的指导方针下分发米非司酮的认证[2] - Walgreens计划在纽约、宾夕法尼亚、马萨诸塞、加利福尼亚和伊利诺伊等州的一些药店提供这种药物[3] - CVS将在马萨诸塞和罗德岛的所有药店提供这种药物[6] - CVS和Walgreens必须确保其计算机系统保护处方者的隐私，同时满足其他具体步骤才能获得认证[11] - 米非司酮是终止怀孕的第一颗药片，用于怀孕期长达70天的情况[15] - 使用堕胎药是一个两种药物的疗程：首先服用米非司酮，然后在24至48小时内服用米索前列醇，引起宫缩以排出怀孕组织[16]